Therapy News and Research

RSS

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.

29 May 2015

High CIP2A may guide TKI choice for chronic phase CML

Treatment with a second-generation tyrosine kinase inhibitor prevents progression to blast crisis in chronic myeloid leukaemia patients with high levels of cancerous inhibitor of PP2A, research suggests.

29 May 2015

CHOP Global Health Center performs first rigorous study of CP outcomes in Africa

Cerebral palsy (CP) is the most common cause of childhood disability in the world, affecting between 1 and 2 infants per thousand. But the neurological condition tends to be understudied, especially in developing countries.

29 May 2015

Global market for asthma treatment expected to reach $21.7 billion by 2020

Despite generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), the global market for asthma treatment is set to witness moderate growth by the end of the decade.

29 May 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease

29 May 2015

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs.

29 May 2015

New EU Clinical Trials Regulation may prove to be challenging for cancer research in Europe

The European Society for Medical Oncology, in collaboration with the European Organisation for Research and Treatment of Cancer, expressed their views on the EU Clinical Trials Regulation in an official position paper recently published in Annals of Oncology.

29 May 2015

DDW 2015: Experts explore efficacy of Stretta therapy for treating chronic GERD patients

A special presentation at Digestive Disease Week 2015 featured GERD experts weighing in on their successful experience using Stretta therapy to treat challenging patient populations suffering from GERD.

29 May 2015

Neurosurgeon performs first endoscopic removal of spinal tumor at Rhode Island Hospital

The spinal tumor grew back. Even though the 16-year old patient endured surgery a year earlier to remove and diagnose the lesion, it was back and its cause unknown. Determined to identify the tumor tissue and set the patient on an appropriate treatment regimen, Albert Telfeian, M.D., a neurosurgeon at Rhode Island Hospital and Hasbro Children's Hospital, performed the first reported case of extracting the tumor endoscopically while the patient was awake and under a local anesthetic.

29 May 2015

MedUni Vienna expert suggests pricing strategy to reduce smoking

30% of the estimated 2.3 million smokers in Austria are considered to be heavily tobacco-dependent and, according to experts at MedUni Vienna, require professional treatment. This would mean around 690,000 people. According to Michael Kunze, an expert on smoking at the Center for Public Health at MedUni Vienna, an effective strategy would be to increase the price of tobacco products: "If the price of cigarettes were to rise just one percent above the inflation rate, that would bring about a 0.5% reduction in consumption worldwide."

29 May 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

29 May 2015

Therapy for genetically-caused emphysema slows progression of lung disease

A landmark clinical study in the Lancet provides convincing evidence that a frequently overlooked therapy for genetically-caused emphysema is effective and slows the progression of lung disease.

29 May 2015

Robert Rountree honored with Linus Pauling Functional Medicine Award

Robert Rountree, MD, has been honored by receiving the Linus Pauling Functional Medicine Award at the Institute for Functional Medicine's 2015 Annual International Conference, being held May 28-30, 2015 in Austin, Texas. Dr. Rountree receives this award for his pioneering work in the development of Functional Medicine, and for his role as a highly inspirational and informational member of IFM's faculty.

29 May 2015

Novel discovery offers new insight into why women more likely than men to develop MS

An innocent mistake made by a graduate student in a Northwestern Medicine lab (she accidentally used male mice instead of female mice during an experiment) has led scientists to a novel discovery that offers new insight into why women are more likely than men to develop autoimmune diseases such as multiple sclerosis (MS).

28 May 2015

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

A new collaborative study led by researchers at Sanford-Burnham Medical Research Institute, published today in Cell Reports, provides new insight into the molecular changes that lead to resistance to a commonly prescribed group of drugs called BRAF inhibitors.

28 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Clinical trial suggests HIV patients should start therapy sooner rather than later

Findings from a large-scale clinical trial have shown that people with HIV should start antiretroviral therapy as soon as they have been diagnosed, irrespective of what their CD4+ count is...

28 May 2015

TxCell reports results from annual general meeting of shareholders

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces results of its annual general meeting of shareholders held in Valbonne, France.

28 May 2015

DITTA attends Sixty-Eighth World Health Assembly session held in Geneva

DITTA, the Global Diagnostic Imaging, Healthcare IT and Radiation Therapy Trade Association is, for the first time, attending the World Health Organization’s Sixty-Eighth World Health Assembly from 18-26 May 2015 since DITTA granted the status of NGO in official relationship with WHO.

28 May 2015

Therapy News and Research

Patient characteristics may guide TKI use in CML

High CIP2A may guide TKI choice for chronic phase CML

CHOP Global Health Center performs first rigorous study of CP outcomes in Africa

Global market for asthma treatment expected to reach $21.7 billion by 2020

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

First European approval of drug to treat genetic kidney disease ADPKD

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

New EU Clinical Trials Regulation may prove to be challenging for cancer research in Europe

DDW 2015: Experts explore efficacy of Stretta therapy for treating chronic GERD patients

Neurosurgeon performs first endoscopic removal of spinal tumor at Rhode Island Hospital

MedUni Vienna expert suggests pricing strategy to reduce smoking

Monoclonal antibody nivolumab improves survival rates of melanoma patients

Therapy for genetically-caused emphysema slows progression of lung disease

Robert Rountree honored with Linus Pauling Functional Medicine Award

Novel discovery offers new insight into why women more likely than men to develop MS

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Clinical trial suggests HIV patients should start therapy sooner rather than later

TxCell reports results from annual general meeting of shareholders

DITTA attends Sixty-Eighth World Health Assembly session held in Geneva

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News